When was T3 Pharma founded?

T3 Pharma was founded in 2015 and raised its 1st funding round 1 year after it was founded.

Where is T3 Pharma located?

T3 Pharma is headquartered in Basel, Switzerland.

How many employees does T3 Pharma have?

As of Aug 31, 2026, the latest employee count at T3 Pharma is 31.

Is T3 Pharma a funded company?

T3 Pharma is a funded company, having raised a total of $42.7M across 3 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jul 01, 2016.

When was the latest funding round of T3 Pharma?

T3 Pharma's latest funding was a $***** Series C round on Jul 22, 2020, with participation from 3 investors. Its primary sector is Oncology. In Switzerland, the Oncology sector has seen $106M in funding in 2026 to date.

Where does T3 Pharma rank among its competitors?

T3 Pharma ranks 773rd amongst 3349 active competitors, of which 1124 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of T3 Pharma?

T3 Pharma's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

T3 Pharma - 2026 Company Profile, Team, Funding & Competitors

T3 Pharma is an acquired company based in Basel (Switzerland), founded in 2015 by Helmut Kessmann, Simon Ittig, Marlise Amstutz and Christoph Kasper. It operates as a Developer of novel and innovative medicines to treat cancer. T3 Pharma has raised $42.7M in funding from Boehringer Ingelheim Venture Fund and Wille Finance. The company has 3349 active competitors, including 1124 funded and 781 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of novel and innovative medicines to treat cancer. The company has developed a proprietary cancer therapy platform based on regulating and harnessing the natural behaviors of live bacteria. The company's lead candidate drug is T3P-Y058-739 for solid tumors.

Website: www.t3pharma.com/
Social
Email ID: *****@t3pharma.com
Part Of

Key Metrics

Founded Year

2015

Location

Basel, Switzerland

Stage

Acquired

Total Funding

$42.7M in 3 rounds

Latest Funding Round

Series C, Jul 22, 2020, $*****

Investors

Boehringer Ingelheim Venture Fund & 4 more

Ranked

773^rd among 3349 active competitors

Employee Count

31 as on Aug 31, 2026

Similar Companies

Jazz Pharmaceuticals & 2998 more

Exit Details

Acquired by Boehringer Ingelheim (Nov 22, 2023)

View T3 Pharma's full profile

T3 Pharma got acquired by Boehringer Ingelheim on Nov 22, 2023 at an acquisition amount of $*****.

Click here to take a look at T3 Pharma's acquisition in detail

T3 Pharma has raised a total funding of $42.7M over 3 rounds. Its first funding round was on Jul 01, 2016. Its latest funding round was a Series C round on Jul 22, 2020 for $*****. 3 investors participated in its latest round. T3 Pharma has 5 institutional investors.

Here is the list of recent funding rounds of T3 Pharma:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 22, 2020	2443807	Series C	2777697	8327856	7457546	8069092
Sep 26, 2019	5551297	Series B	7932951	7705869	4625560	Reference Capital
Jul 01, 2016	5553803	Grant (prize money)	6919721	2840463	3962281	9577644

Access funding benchmarks and valuations. Sign up today!

View details of T3 Pharma's funding rounds and investors

The founders of T3 Pharma are Helmut Kessmann, Simon Ittig, Marlise Amstutz and Christoph Kasper.

Here are the details of T3 Pharma's key team members:

Helmut Kessmann: Co-Founder of T3 Pharma.
Simon Ittig: CEO & Co-Founder of T3 Pharma.
Marlise Amstutz: Co-Founder of T3 Pharma.
Christoph Kasper: CSO & Co-Founder of T3 Pharma.

View details of T3 Pharma's Founder profiles and Board Members

T3 Pharma's employee count trend

T3 Pharma has 31 employees as of Aug 26. Here is T3 Pharma's employee count trend over the years:

Uncover T3 Pharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of T3 Pharma include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of T3 Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
773rd	T3 Pharma 2015, Basel (Switzerland), Acquired	Developer of novel and innovative medicines to treat cancer	$42.7M	Boehringer Ingelheim Venture Fund, BaseLaunch ... & 3 others	46/100